Jasper Therapeutics, Amplitude Healthcare Acquisition (AMHCU) Announce Merger to Create Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation

Transaction includes up to $100 million in trust at Amplitude and a concurrent, fully committed $100 million PIPE financing from premier institutional investors, led by new investor Federated Hermes Kaufmann Funds, affiliates of Amplitudes sponsor Avego and Metalmark, other new biotechnology focused investors, and with participation from the founding Series A investors Abingworth LLP, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Roche Venture Fund and Alexandria Venture Investments, LLC

Anticipated cash resources will be used to advance JSP191, Jaspers first-in-class CD117 monoclonal antibody conditioning agent, which is... More